Université de Liège
Established in 1817, the University of Liège (ULiège) is one of Belgium’s leading universities. It hosts nearly 27,000 students, with 25% being international, representing 123 nationalities. As the public university of the Wallonia-Brussels Federation, ULiège encompasses 11 faculties covering the humanities, health sciences, and science and technology. With 39 bachelor’s and 193 master’s programs, ULiège offers one of the most diverse educational selections in Belgium.
ULiège operates across three cities in Wallonia: Liège, Gembloux, and Arlon. Its programs hold several international quality accreditations, including EQUIS, AACSB, EUR-ACE, and the Conférence des Grandes Écoles. The university maintains partnerships with over 1,000 teaching and research institutions worldwide, driving robust research in fields such as biotechnology, life and medical sciences (human and veterinary), agronomy, space and engineering sciences, and environmental studies. ULiège’s active collaborations with public and private sectors have led to the creation of nearly 110 spin-off companies.
As a major employer in Wallonia, ULiège employs nearly 5,700 staff, including 903 academic members and 2,687 in teaching and research roles. In partnership with the CHU of Liège, the university supports approximately 12,000 direct jobs across the provinces of Liège, Namur, and Luxembourg.
Role within PerPrev-CID
ULiege and its affiliated hospital, CHU of Liege, serve as key recruitment center for patients with Inflammatory Bowel Disease (IBD) and Rheumatoid Arthritis (RA). They play an integral role in recruiting and monitoring patients who are enrolled in various work packages (WPs), specifically WP3, WP4, WP10, and WP11. Additionally, ULiege is responsible for leading WP4. Beyond recruitment and monitoring, they are also heavily involved in the comprehensive analysis of data generated from these work packages, as well as from all other associated work packages in the project.
Through their ongoing participation in the ENSEMBLE project, ULiege will also contribute to WP1 and WP2, which focus on "Pre-disease" biomarkers. These work packages aim to identify predictive multi-dimensional biomarkers in populations at high risk for developing RA or IBD.
